CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma
Abstract
Multi-targeted tyrosine kinase inhibitors (TKIs) are the standard of care for patients with advanced clear cell renal cell carcinoma (ccRCC). However, a significant number of ccRCC patients are primarily refractory to targeted therapeutics, showing neither disease stabilisation nor clinical benefits.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 24, 2020
- Source ID
- 10.1038/s41416-020-01087-x
Entities
People
- Ilya G. Serebriiskii
- Ji A. Sohn
- Peter Makhov
- Robert G. Uzzo
- Rushaniya Fazliyeva
- Vladimir Khazak
- Vladimir M. Kolenko
- Yanis Boumber
Organizations
- National Cancer Institute
- United States Department of Defense
- United States Department of Health and Human Services